Have a feature idea you'd love to see implemented?
Let us know!
DNA Ginkgo Bioworks Holdings Inc
Price (delayed)
$6.59
Market cap
$378.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$13.08
Enterprise value
$208.16M
the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline
Highlights
The EPS rose by 28% since the previous quarter and by 21% year-on-year
The net income has grown by 27% from the previous quarter and by 24% YoY
The revenue has declined by 31% year-on-year but it rose by 18% since the previous quarter
The gross profit has declined by 26% year-on-year but it is up by 19% since the previous quarter
The equity is down by 36% year-on-year and by 4.2% since the previous quarter
The debt is up by 10% year-on-year
Key stats
What are the main financial stats of DNA
Market
Valuations
Earnings
Shares outstanding
57.48M
Market cap
$378.79M
Enterprise value
$208.16M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.46
Price to sales (P/S)
1.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.96
Revenue
$217.95M
EBIT
-$651.45M
EBITDA
-$565.9M
Free cash flow
-$385.24M
Per share
Balance sheet
Liquidity
EPS
-$13.08
Free cash flow per share
-$7.37
Book value per share
$14.36
Revenue per share
$4.17
TBVPS
$26.82
Total assets
$1.48B
Total liabilities
$682.94M
Debt
$445.59M
Equity
$797.94M
Working capital
$548.05M
Debt to equity
0.56
Current ratio
5.79
Quick ratio
5.59
Net debt/EBITDA
0.3
Margins
Efficiency
Dividend
EBITDA margin
-259.6%
Gross margin
80.9%
Net margin
-298.8%
Operating margin
-291%
Return on assets
-41%
Return on equity
-70.1%
Return on invested capital
-73.7%
Return on capital employed
-47.7%
Return on sales
-298.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DNA stock price
How has the Ginkgo Bioworks Holdings stock price performed over time
Intraday
3.62%
1 week
-9.85%
1 month
-26.12%
1 year
-88.48%
YTD
-90.25%
QTD
-19.14%
Financial performance
How have Ginkgo Bioworks Holdings's revenue and profit performed over time
Revenue
$217.95M
Gross profit
$176.41M
Operating income
-$634.27M
Net income
-$651.19M
Gross margin
80.9%
Net margin
-298.8%
The net margin is up by 39% since the previous quarter but it is down by 10% year-on-year
DNA's operating margin is up by 38% from the previous quarter
DNA's operating income is up by 31% year-on-year and by 27% since the previous quarter
The revenue has declined by 31% year-on-year but it rose by 18% since the previous quarter
Growth
What is Ginkgo Bioworks Holdings's growth rate over time
Valuation
What is Ginkgo Bioworks Holdings stock price valuation
P/E
N/A
P/B
0.46
P/S
1.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.96
The EPS rose by 28% since the previous quarter and by 21% year-on-year
The price to book (P/B) is 74% lower than the last 4 quarters average of 1.8
The equity is down by 36% year-on-year and by 4.2% since the previous quarter
The stock's price to sales (P/S) is 79% less than its last 4 quarters average of 7.5
The revenue has declined by 31% year-on-year but it rose by 18% since the previous quarter
Efficiency
How efficient is Ginkgo Bioworks Holdings business performance
The return on sales rose by 39% since the previous quarter but it has declined by 8% year-on-year
The company's return on invested capital rose by 29% QoQ but it fell by 3.1% YoY
The ROE has contracted by 25% YoY but it has grown by 19% from the previous quarter
The company's return on assets rose by 21% QoQ but it fell by 11% YoY
Dividends
What is DNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DNA.
Financial health
How did Ginkgo Bioworks Holdings financials performed over time
Ginkgo Bioworks Holdings's total assets is 117% higher than its total liabilities
Ginkgo Bioworks Holdings's total assets has decreased by 27% YoY and by 9% QoQ
DNA's quick ratio is up by 24% since the previous quarter but it is down by 15% year-on-year
The debt is 44% smaller than the equity
The debt to equity has soared by 75% YoY and by 3.7% from the previous quarter
The equity is down by 36% year-on-year and by 4.2% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.